Karyopharm Therapeutics Inc (KPTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($-269.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Karyopharm Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read KPTI current and long-term liabilities for a breakdown of total debt and financial obligations.
Karyopharm Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Karyopharm Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:BTRDA
|
N/A |
|
Sermsang Power Corporation Public Company Limited
BK:SSP
|
0.058x |
|
Forth Smart Service Public Company Limited
BK:FSMART
|
0.092x |
|
Brand Engagement Network Inc
NASDAQ:BNAI
|
-0.031x |
|
Quercus TFI SA
WAR:QRS
|
0.507x |
|
Intellego Technologies AB
ST:INT
|
13.682x |
|
TIZIANA LIFE SCIENCES LTD
F:0RP
|
N/A |
|
Payton -L
TA:PAYT
|
0.033x |
Annual Cash Flow Conversion Efficiency for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Karyopharm Therapeutics Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see KPTI market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-292.93 Million | $-75.37 Million | 0.257x | -62.46% |
| 2024-12-31 | $-186.02 Million | $-127.49 Million | 0.685x | +0.67% |
| 2023-12-31 | $-136.21 Million | $-92.72 Million | 0.681x | -92.42% |
| 2022-12-31 | $-16.66 Million | $-149.55 Million | 8.979x | +567.86% |
| 2021-12-31 | $-79.67 Million | $-107.12 Million | 1.344x | +142.41% |
| 2020-12-31 | $50.55 Million | $-160.23 Million | -3.170x | +17.31% |
| 2019-12-31 | $49.77 Million | $-190.82 Million | -3.834x | -341.33% |
| 2018-12-31 | $183.17 Million | $-159.12 Million | -0.869x | -52.56% |
| 2017-12-31 | $129.46 Million | $-73.72 Million | -0.569x | -9.47% |
| 2016-12-31 | $162.24 Million | $-84.39 Million | -0.520x | -9.73% |
| 2015-12-31 | $198.37 Million | $-94.03 Million | -0.474x | -90.53% |
| 2014-12-31 | $206.79 Million | $-51.45 Million | -0.249x | -27.25% |
| 2013-12-31 | $154.93 Million | $-30.29 Million | -0.196x | -135.14% |
| 2012-12-31 | $-27.88 Million | $-15.51 Million | 0.556x | -17.67% |
| 2011-12-31 | $-12.65 Million | $-8.55 Million | 0.676x | -- |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more